Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Global Hepatitis D Market - Industry Trends and Forecast to 2028

Pharmaceutical | Upcoming Report | Nov 2021 | Global | 350 Pages | No of Tables: 220 | No of Figures: 60

Report Description

Global Hepatitis D Market, By Type (Acute Hepatitis D, Chronic Hepatitis D), Treatment (Interferon Alpha, Lamivudine, Liver Transplant, Others), Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others), Transmission (Exposure to Infected Blood, Contaminated Needles, Blood and Plasma Product Transfusion, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Global Hepatitis D Market

Hepatitis D market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3% in the above mentioned forecast period.

Hepatitis D is a viral infection which is caused by the hepatitis D virus and causes inflammation of the liver. This further result in the impairment of liver functions and causes long term liver problems such as liver cancer and scarring. Hepatitis D virus (HDV) is found only in the people who are infected with hepatitis B virus. Symptoms of hepatitis D include abdominal pain, jaundice, joint pain, dark-coloured urine, loss of appetite, fatigue, nausea and vomiting.

Rise in the prevalence of hepatitis D and hepatitis B, growing healthcare expenditure, alcohol abuse, high consumption of unbalanced diet, rising incidence of intravenous drug abuse, growing government funding and rising initiatives by government and private organisations to spread awareness about the disease are the factors that will expand the hepatitis D market.

Rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the hepatitis D market in the forecast period of 2021-2028.

However, high cost of treatment, lack of awareness about the preventive measures and complications associated with hepatitis D such as liver failure, liver cirrhosis and hepatocellular carcinoma are the factors that will hinder the market growth and will further challenge the hepatitis D market in the forecast period mentioned above.

This hepatitis D market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatitis D market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hepatitis D Market Scope and Market Size

The hepatitis D market is segmented on the basis of type, treatment, diagnosis, transmission, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of type, the hepatitis D market is segmented into acute hepatitis D and chronic hepatitis D.
  • On the basis of treatment, the hepatitis D market is segmented into interferon alpha, lamivudine, liver transplant and others. Others have been sub-segmented into emerging drugs which are further divided into peginterferon lambda, bulevirtide, lonafarnib and JNJ-73763989.
  • On the basis of diagnosis, the hepatitis D market is segmented into blood tests, elastography, liver biopsy, serologic testing and others.
  • On the basis of transmission, the hepatitis D market is segmented into exposure to infected blood, contaminated needles, blood and plasma product transfusion and others.
  • On the basis of end-users, the hepatitis D market is segmented into clinic, hospital and others.

The hepatitis D market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Hepatitis D Market Country Level Analysis

Hepatitis D market is analyzed and market size information is provided by the country, type, treatment, diagnosis, transmission, end-users and distribution channel as referenced above.

The countries covered in the hepatitis D market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the hepatitis D market due to the presence of major key players, growing prevalence of disease, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and emerging markets in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Hepatitis D market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Hepatitis D Market Share Analysis

Hepatitis D market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hepatitis D market research.

The major players covered in the hepatitis D market report are BIOSIDUS, F. Hoffmann-La Roche Ltd., Zydus Cadila, NanoGen Healthcare Pvt. Ltd., AMEGA Biotech, Rhein-Minapharm, PROBIOMED SA de CV, 3SBio Group, Eiger BioPharmaceuticals, Arrowhead Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., Antios Therapeutics, Inc., PharmaEssentia Corporation, Replicor, Janssen Pharmaceuticals, Inc., Gilead Sciences, Inc., Hetero, Aurobindo Pharma, Mylan N.V., Apotex Inc., ViiV Healthcare group of companies, GlaxoSmithKline plc, Cipla Inc., Sun Pharmaceutical Industries Ltd., and Merck Sharp & Dohme Corp., among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Table of Content

Please fill in the below form for detailed Table of Content

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Table

Please fill in the below form for detailed List of Table

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

List of Figure

Please fill in the below form for detailed List of Figure

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country

View Infographics

Please fill in the below form for detailed Infographics

First name is required
Last name is required
Please enter Contact No.
Email is required
Please enter job tital
Please enter company name
Please select country
CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19